What the study found
In this case, a previously stable pulmonary tuberculous focus reactivated after chemoimmunotherapy with tislelizumab, and it later regressed even though the patient did not complete a full anti-tuberculosis course. The patient then continued tislelizumab maintenance, and both the cancer lesion and the tuberculous lesion were stable at 10 months.
Why the authors say this matters
The authors conclude that a short course of anti-tuberculosis therapy may be a viable management strategy for immune checkpoint inhibitor (ICI, immune checkpoint inhibitor)–induced reactivation of a stable tuberculosis focus. They suggest this may help patients continue ICIs safely and may challenge the usual requirement for a complete anti-TB course in this specific situation.
What the researchers tested
This is a case report of a 69-year-old man with stage IV lung squamous cell carcinoma and a long-term radiologically stable, untreated pulmonary tuberculous focus. He received paclitaxel, carboplatin, and tislelizumab, and the reactivated tuberculous lesion was confirmed by next-generation sequencing.
What worked and what didn't
The malignant mass regressed after four cycles of chemoimmunotherapy. The previously stable tuberculous focus reactivated, and anti-tuberculosis treatment was stopped by the patient after two months because of severe synergistic toxicity with chemotherapy; after that, the granulomatous lesion regressed to its original baseline size.
What to keep in mind
This is a single case report, so the findings are limited to one patient. The abstract does not describe broader testing, and it does not provide a general treatment rule beyond this specific scenario.
Key points
- A stable pulmonary tuberculous focus reactivated after treatment with paclitaxel, carboplatin, and tislelizumab.
- The tuberculous reactivation was confirmed by next-generation sequencing.
- The patient stopped anti-tuberculosis therapy after two months because of severe synergistic toxicity with chemotherapy.
- The reactivated granulomatous lesion regressed back to baseline size without a full anti-TB course.
- At 10 months, both the tuberculosis lesion and the cancer lesion were stable while tislelizumab maintenance continued.
Disclosure
- Research title:
- Short-course anti-TB therapy preceded regression of a reactivated tuberculous focus
- Authors:
- Xiao-Jun Guo, Rui Ma, Yanling Ma, Shaopeng Hua
- Institutions:
- Qinghai No.3 People's Hospital, Qinghai No.3 People's Hospital, Qinghai No.3 People's Hospital, Wuxi Fourth People's Hospital, Wuxi People's Hospital
- Publication date:
- 2026-02-04
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with scholarly research without reading academic papers — one filtered digest, every Friday.